Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01270802 · ClinicalTrials.gov registry record · Phase 4
Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients
A Phase 4 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT01270802: Completed Phase 4 study, sponsored by Indiana University.
NCT01270802 is a Phase 4 study that has completed, run by Indiana University. The registered enrollment target is 30 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01270802, a Phase 4 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular function and tests of bone health.
Primary Outcome
Change in FMD is a measure of change in endothelial function
Interventions
- DRUG Raltegravir
- DRUG Tenofovir/emtricitabine
- DRUG Tenofovir/emtricitabine/efavirenz
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-04 |
| Est. Completion | 2013-04 |
| Phase | Phase 4 |
What the finished NCT01270802 record still lists
NCT01270802 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Raltegravir is the first listed.
NCT01270802 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01270802 about?
NCT01270802 is a clinical study titled "Effects of Switching Efavirenz to Raltegravir on Vascular Function and Bone Markers in HIV-infected Patients". Efavirenz, a commonly used HIV medication, may cause worsening vascular function and bone problems. The purpose of this study is to determine if switching efavirenz to raltegravir, a newer HIV medication, will improve vascular function and tests of bone health.
What is the current status of trial NCT01270802?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2011-04. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01270802?
The interventions under investigation include: Raltegravir (DRUG), Tenofovir/emtricitabine (DRUG), Tenofovir/emtricitabine/efavirenz (DRUG).
Who is sponsoring clinical trial NCT01270802?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01270802's enrollment target sits among peer trials
30 1552nd of 2000 higher than 367 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia